Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Final CTU new 2019 masthead1

Contraceptive Technology Update – November 1, 2019

November 1, 2019

View Archives Issues

  • Research Examines Effect of Immediate Postpartum Use of DMPA in Breastfeeding Moms

    While the contraceptive injection DMPA is a popular birth control option for many women, there is no definitive evidence on its immediate postpartum effect on breastfeeding. The National Institute of Child Health and Human Development has awarded funding to Ohio State University researchers to evaluate the effects of immediate postpartum initiation of DMPA on breastfeeding and on long-term patterns of contraceptive use.

  • Experts Push for Adolescent HPV Vaccination

    New information indicates that an estimated 92% of HPV-related cancers could be prevented by vaccine. Several national professional organizations have come together to emphasize the critical importance of immunization visits to help teens receive the HPV shot and other needed immunizations.

  • Pharmacist Prescribing of Hormonal Contraceptives Available in Utah

    Contraceptive access has expanded for adult women in Utah, as pharmacists have begun to prescribe hormonal contraceptives. As of September 2019, pharmacies in more than 75 Utah cities signed up to participate in the program. In 2018, the Utah legislature passed Senate Bill 184 to allow women aged 18 years and above to obtain hormonal contraceptives from a qualified pharmacist without a visit to a healthcare provider.

  • Research Discovery May Lead to New UTI Treatments

    Recurrent urinary tract infections (UTIs) are extremely common. In a primary care setting, 53% of women above age 55 years and 36% of younger women reported a recurrence within one year. Recent research indicates that some UTIs may stem from a persistent reservoir of E. coli residing in the intestine.

  • Early Clinical Trial Data Suggest Potential Chlamydia Vaccine Safe for Use

    Results of an early trial of a potential chlamydia vaccine indicate it is safe for use. While the vaccine, the first to reach Phase 1 clinical trial status, demonstrates promising early signs, further studies are needed to determine whether the immune response fully protects against chlamydia infection.

  • Mental Health Conditions May Be Linked to Unnecessary Oophorectomies

    Results from a new study identify mental health conditions associated with an increased risk of unnecessary bilateral oophorectomies, despite nonmalignant indications. Related research indicates that hysterectomy is associated with an increased risk of long-term mental health issues, including depression and anxiety.